Almac’s rapidd continuing to accelerate early stage development 2 years on

rapidd^TM works by offering a lean, flexible package, fully compliant with ICH guidelines, and integrated services between Almac and selected global CROs which is managed by Almac through a dedicated programme management team.

In 2011 alone, three integrated programmes have been completed with a further 5 ongoing, or in late planning stages. Over the past two years, interest has remained strong in both the NCE and biopharmaceutical markets from a range of clients from virtual biotech companies to large pharma with both small molecule and peptide candidates.

“rapidd^TM enables our clients to make significant savings against conventional lead times from careful programme optimisation and avoidance of tech transfer time and other common issues which arise in a multiple partner process”, commented Denis Geffroy, VP Business Development. “We are delighted that our rapidd^TM programme has proven so successful in helping to eliminate these barriers. With our range of single-site services and capabilities, we are confident that our package brings even more added value in our clients’ pre-clinical development programmes.”

In the current uncertain financial climate, Almac’s clients have benefited from the flexible approach rapidd^TM offers – from taking advantage of Almac’s pre-clinical expertise to enabling payment schedules to be structured in line with agreed investor milestone payments.

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 861 3938 or e-mail: t.jervis@defacto.com.